Information Provided By: 
Fly News Breaks for March 13, 2015
NSPR
Mar 13, 2015 | 07:47 EDT
As noted earlier, Oppenheimer downgraded InspireMD to Perform from Outperform. As reasons for the downgrade, the firm cited lower than expected uptake of the company’s bare-metal coronary stent and lack of sufficient visibility on the outcomes of the ongoing drug-eluting stent partnership discussions.
News For NSPR From the Last 2 Days
There are no results for your query NSPR
